Last updated: June 27, 2026
Esperion Therapeutics v. Aurobindo Pharma Limited (2:24-cv-06348): Litigation Summary, Patent Issues, and Likely Generic Entry Risks
Esperion Therapeutics, Inc. v. Aurobindo Pharma Limited, No. 2:24-cv-06348 (filed in the District of New Jersey), is a Hatch-Waxman patent infringement case tied to a launch risk against Aurobindo. The procedural posture and substantive claims can’t be summarized accurately without the complaint, asserted patent numbers, Orange Book drug/strength, and Paragraph IV contents from the docket.
No complete, citation-ready litigation summary can be produced under the constraints because the case-specific filings (complaint/answers, infringement allegations, asserted claims, and any settlement or counterclaim outcomes) are not present in the provided information.
What patents are asserted in Esperion Therapeutics v. Aurobindo (2:24-cv-06348)?
A correct answer requires the asserted U.S. patent numbers and claim sets included in the complaint’s infringement allegations.
Which Orange Book drug is the case tied to?
A correct answer requires the specific FDA product (listed drug), strength(s), and listed patents that map to the asserted patents in the case.
Are the asserted patents composition, formulation, or method-of-use?
A correct answer requires the patent type and the claim scope asserted in the infringement counts.
What claims does Esperion allege that Aurobindo infringes?
A correct answer requires the specific infringement theories (e.g., ANDA product structure, labeling/method-of-use, or manufacturing process claims) pleaded in the complaint.
What product attributes are alleged to be copied?
A correct answer requires the complaint’s Markman-relevant details and claim-to-product mapping.
Is the alleged infringement tied to FDA labeling or patient instructions?
A correct answer requires the complaint’s method-of-use and/or induced infringement allegations, including labeling language citations.
When was the case filed, and what is the procedural status in 2:24-cv-06348?
A correct answer requires docket events with dates (summons/service, initial disclosures, motion practice, claim construction scheduling, and any dismissal/settlement entries).
Has the court set a Markman date or claim construction deadline?
A correct answer requires docket orders or scheduling conferences.
Were any motions resolved (e.g., venue, pleadings, preliminary injunction, or stay)?
A correct answer requires the presence and outcomes of docketed motions.
How strong is Esperion’s patent estate in this lawsuit?
A correct answer requires the asserted patents and the independent/dependent claim structure, plus prosecution history or freedom-to-operate context, and the case’s invalidity defenses.
What invalidity grounds does Aurobindo raise (if pleaded)?
A correct answer requires the answer and any invalidity contentions.
Is the case likely to turn on claim construction?
A correct answer requires claim construction briefing and order history.
What generic entry risks exist for Aurobindo if litigation continues or settles?
A correct answer requires linkage between the case and the ANDA approval timeline, any P-IV paragraph IV certification status, and any court-ordered or settlement-triggered launch date changes.
Does this case include a Paragraph IV certification and 30-month stay?
A correct answer requires the certification and statutory dates pleaded or reflected on the docket.
What launch design-around risks exist (different salts, coatings, crystal form, particle size)?
A correct answer requires the formulation and/or manufacturing claims asserted.
What settlements or consent judgments affect exclusivity and launch timing?
A correct answer requires docket entries showing a settlement, consent judgment, dismissal with prejudice, or standstill.
Did the parties agree to carve-out claims or delayed launch windows?
A correct answer requires the settlement terms and dismissal conditions.
What is the Orange Book status of the asserted patents for the listed drug?
A correct answer requires the specific listed drug and the Orange Book listings (patent numbers, expiration dates, and exclusivity blocks).
What are the patent expiration dates driving the litigation?
A correct answer requires the asserted patents’ expiration dates and any statutory exclusivity.
When does exclusivity expire relative to the litigation timeline?
A correct answer requires the exclusivity type (NCE, pediatric, 505(b)(2) exclusivity, etc.) and statutory timelines for the listed drug.
How does this case compare with other Esperion vs. generic litigations?
A correct answer requires identifying the comparable matters (same listed drug, same patent family, same defendants) and their outcomes, which are not provided.
Are there repeating asserted patents across cases?
A correct answer requires the asserted patent sets from those other matters.
What do prior claim outcomes imply for Aurobindo?
A correct answer requires case outcome data, not provided here.
Key Takeaways
No case-specific litigation summary or analysis can be delivered from only the caption and docket number without the asserted patents, the underlying FDA product context, and the docketed procedural record.
FAQs
- What is the typical Hatch-Waxman stay impact in Esperion patent cases involving Paragraph IV filings?
- How do method-of-use patents change the infringement analysis for generic labeling in generic statins or lipid therapies?
- What happens procedurally if the defendant seeks early dismissal or summary judgment on noninfringement?
- How do settlement-triggered launch dates interact with court-ordered stays in Hatch-Waxman cases?
- What factors influence whether a court grants a preliminary injunction in ANDA patent cases?
References (APA)
- U.S. District Court for the District of New Jersey. Esperion Therapeutics, Inc. v. Aurobindo Pharma Limited, No. 2:24-cv-06348.
